Currencies / BIIB
BIIB: Biogen Inc
126.64
USD
1.92
(1.49%)
BIIB exchange rate has changed by -1.49% for today. During the day, the instrument was traded at a low of 125.97 and at a high of 129.62.
Follow Biogen Inc dynamics. Real-time quotes will help you quickly react to market changes. By switching between different timeframes, you can monitor exchange rate trends and dynamics by minutes, hours, days, weeks, and months. Use this information to forecast market changes and to make informed trading decisions.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
BIIB News
- Seeking Alpha Alkermes: A More Than Solid Quarter (NASDAQ:ALKS)
- Investing Apple, Amazon, Kla-tencor set to report earnings Thursday
- Investing Lecanemab real-world study shows promising results in early Alzheimer’s
- Zacks Biogen (BIIB) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
- Investing Biotech stocks dip as Trump administration mulls patent fee overhaul
- Zacks Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
- Zacks BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
- Zacks Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
- TipRanks QQQ ETF News, 7/24/2025 - TipRanks.com
- Benzinga Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US - AstraZeneca (NASDAQ:AZN)
- Benzinga FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division - Sarepta Therapeutics (NASDAQ:SRPT), Biogen (NASDAQ:BIIB)
- Investing BMO Capital reiterates Eli Lilly stock rating with $900 price target
- Zacks How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?
- TipRanks QQQ ETF News, 7/22/2025 - TipRanks.com
- Benzinga Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing - Biogen (NASDAQ:BIIB)
- Seeking Alpha Eli Lilly: Competition Melts Away (NYSE:LLY)
- Investing Truist Securities initiates Biogen stock coverage with Hold rating
- Investing Biogen to invest $2 billion more in North Carolina
- Investing Biogen to invest $2 billion in North Carolina manufacturing expansion
- Investing Harrow Health stock outlook strong as Cantor reiterates Overweight rating
- Investing Ionis Pharma CEO Monia sells $48,416 in stock
- Benzinga Is Bristol-Myers Squibb Still An Undervalued Biopharma Play? - Bristol-Myers Squibb (NYSE:BMY)
- Investing Biogen stock price target raised to $130 from $119 at UBS on Alzheimer’s outlook
- Seeking Alpha Patient Capital Management Q2 2025 Investment Review
Daily Range
125.97
129.62
Year Range
110.03
219.44
- Previous Close
- 127.90
- Open
- 128.56
- Bid
- 126.64
- Ask
- 126.94
- Low
- 125.97
- High
- 129.62
- Volume
- 4.221 K
- Daily Change
- -1.49%
- Month Change
- 1.26%
- 6 Months Change
- -11.29%
- Year Change
- -41.23%
30 July, Wednesday
12:15
USD
- Act
- 104 K
- Fcst
- 57 K
- Prev
- -33 K
12:30
USD
- Act
- 3.0%
- Fcst
- 0.4%
- Prev
- -0.5%
12:30
USD
- Act
- 2.0%
- Fcst
- 3.6%
- Prev
- 3.8%
12:30
USD
- Act
- 2.5%
- Fcst
- 3.3%
- Prev
- 3.5%
12:30
USD
- Act
- 2.1%
- Fcst
- 3.1%
- Prev
- 3.7%
12:30
USD
- Act
- 1.4%
- Fcst
- 0.8%
- Prev
- 0.5%
12:30
USD
- Act
- 6.3%
- Fcst
- -1.5%
- Prev
- -3.1%
14:00
USD
- Act
- -0.8%
- Fcst
- 1.6%
- Prev
- 1.8%
14:00
USD
- Act
- -2.8%
- Fcst
- 9.6%
- Prev
- 1.1%
14:00
USD
- Act
- 72.0
- Fcst
- Prev
- 72.6
14:30
USD
- Act
- 7.698 M
- Fcst
- 0.914 M
- Prev
- -3.169 M
14:30
USD
- Act
- 0.690 M
- Fcst
- 0.114 M
- Prev
- 0.455 M
14:30
USD
- Act
- 1.317 M
- Fcst
- 0.738 M
- Prev
- -0.740 M
14:30
USD
- Act
- 0.130 M
- Fcst
- -0.004 M
- Prev
- 0.095 M
14:30
USD
- Act
- 3.635 M
- Fcst
- -0.111 M
- Prev
- 2.931 M
14:30
USD
- Act
- 0.676 M
- Fcst
- 0.915 M
- Prev
- 0.282 M
14:30
USD
- Act
- 0.739 M
- Fcst
- 0.608 M
- Prev
- 0.003 M
14:30
USD
- Act
- -2.724 M
- Fcst
- 0.879 M
- Prev
- -1.738 M
14:30
USD
- Act
- -0.025 M
- Fcst
- Prev
- 0.087 M
14:30
USD
- Act
- -0.1%
- Fcst
- Prev
- 1.6%
18:00
USD
- Act
- Fcst
- Prev
18:00
USD
- Act
- 4.50%
- Fcst
- Prev
- 4.50%
18:30
USD
- Act
- Fcst
- Prev